Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212842 | PMC |
| http://dx.doi.org/10.1093/noajnl/vdaa029 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
m5C methylation modification may be an accomplice in colorectal cancer escaping from anti-tumor effects of innate immunity-type I/III interferon.
Front Immunol
January 2025
Traditional Chinese Medicine Department of Orthopaedic and Traumatic, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Colorectal cancer (CRC) is one of the most prevalent malignant tumors in the world, and its occurrence and development are closely related to the complex immune regulatory mechanisms. As the first barrier of the body's defense, innate immunity plays a key role in tumor immune surveillance and anti-tumor response, in which type I/III interferon (IFN) is an important mediator with significant antiviral and anti-tumor functions. 5-methylcytosine (m5C) modification of RNA is a key epigenetic regulation that promotes the expression of CRC oncogenes and immune-related genes.
View Article and Find Full Text PDFCOVID-19 related epigenetic changes and atopic dermatitis: An exploratory analysis.
World Allergy Organ J
January 2025
Department of Dermatology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Background: While epidemiological data suggest a connection between atopic dermatitis (AD) and COVID-19, the molecular mechanisms underlying this relationship remain unclear.
Objective: To investigate whether COVID-19-related CpGs may contribute to AD development and whether this association is mediated through the regulation of specific genes' expression.
Methods: We combined Mendelian randomization and transcriptome analysis for data-driven explorations.
Characterization of tumor epigenetic aberrations is integral to understanding the mechanisms of tumorigenesis and provide diagnostic, prognostic, and predictive information of high clinical relevance. Among the different tumor-associated epigenetic signatures, 5 methyl-cytosine (5mC) and 5-hydroxymethylcytosine (5hmC) are the two most well-characterized DNA methylation alterations linked to cancer pathogenesis. 5hmC has a tissue-specific distribution and its abundance is subjected to changes in tumor DNA, making it a promising biomarker.
View Article and Find Full Text PDFVaried Clinical Features and Outcomes of Autoimmune Encephalitis: A Retrospective Case Series.
Cureus
December 2024
Neurology, SRM Medical College Hospital and Research Centre, SRM Institute of Science and Technology, Chengalpattu, IND.
Introduction: This study discusses the various clinical profiles, investigatory findings, treatment responses, and prognosticating factors in seven cases of autoimmune encephalitis (AE).
Methods: The clinical records of seven AE patients admitted to the Neurology Department, SRM Medical College Hospital and Research Centre, Chennai, from July 2022 to December 2023 were retrospectively analyzed.
Results: The patients' ages ranged from 18 to 35, and all experienced seizures.
Investigating POU3F4 in cancer: Expression patterns, prognostic implications, and functional roles in tumor immunity.
Heliyon
January 2025
Department of Cardiothoracic Surgery, Affiliated Hospital 6 of Nantong University, Yancheng Third People's Hospital, The Yancheng School of Clinical Medicine of Nanjing Medical University, Yancheng, 224002, China.
Research has demonstrated that POU3F4 is integral to various cancers, in addition to its significance in inner ear development, pancreatic differentiation, as well as neural stem cell differentiation. Nevertheless, comprehensive pan-cancer analyses focusing on POU3F4 remain limited. This study aims to assess the prognostic value of POU3F4 in thirty-three cancers and explore its immune-related functions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!